Clinical Effect of Ginger and Citri Reticulatae Stomach-warming Ointment Combined with Tropisetron and Dexamethasone in Preventing Chemotherapy-induced Nausea and Vomiting

doi:10.12114/j.issn.1007-9572.2020.00.177

Abstract

Abstract: Background　Chemotherapy-induced nausea and vomiting（CINV） is one of the common adverse reactions in the treatment of tumors.Acupoint application，as a characteristic therapy of traditional Chinese medicine，can play a certain role in the prevention and treatment of CINV.The study on acupoint application in preventing CINV is of great significance for improving the quality of life of cancer patients during chemotherapy.Objective　To explore the clinical efficacy of acupoint application of ginger and citri reticulatae stomach-warming ointment combined with Tropisetron and Dexamethasone in preventing CINV.Methods　A total of 140 patients with chemotherapy of gastrointestinal tumors who were hospitalized in the Department of Oncology in the First Affiliated Hospital of Guangzhou University of Chinese Medicine and the General Hospital of Guangzhou Military Region were selected as the study objects from May to December in 2018.They were divided into the ginger and citri reticulatae stomach-warming ointment group（75 cases） and the control group（65 cases） using the random number table method（excluding those were unable to continue the study before the first chemotherapy）.In the follow-up process，10 cases in ginger and citri reticulatae stomach-warming ointment group and 4 cases in control group dropped out.The control group received the conventional CINV prevention plan（intravenous injection of tropisetron and dexamethasone） during chemotherapy，and the other group was added with acupoint application of ginger and citri reticulatae stomach-warming ointment on the basis of conventional prevention plan.Nausea and vomiting and related adverse reactions were recorded daily from the first day to the fifth day of chemotherapy.The EORTC core quality of life questionnaire（QLQ-C30） was used to evaluate the quality of life on the fifth day of chemotherapy.Results　There was no significant difference in the effective control rate （ORR） of CINV between ginger and citri reticulatae stomach-warming ointment group and control group（98.5% vs 91.2%，P=0.10）.The ORR of delayed CINV in the ginger and citri reticulatae stomach-warming ointment group was higher than that in the control group（100.0% vs 81.3%），and the difference was statistically significant（P=0.02）.The incidence of vomiting in ginger and citri reticulatae stomach-warming ointment group was lower than that in the control group with a statistically significant difference on the second，third and fourth days （P<0.05）.The incidence of nausea in ginger and citri reticulatae stomach-warming ointment group was lower than that in the control group from the first day to the fifth day（P<0.05）.The overall quality of life of the patients in ginger and citri reticulatae stomach-warming ointment group was significantly improved compared with the control group（P<0.05），which was mainly manifested in fatigue and gastrointestinal symptoms such as nausea and vomiting，loss of appetite，diarrhea，and constipation（P<0.05）.However，there was no significant difference in the utilization rate of salvage treatment between the two groups（P>0.05）.Conclusion　The acupoint application of ginger and citri reticulatae stomach-warming ointment combined with Tropisetron and Dexamethasone is effective for delayed CINV.It can relieve fatigue and gastrointestinal symptoms and improve the overall quality of life of patients，which can be further studied and promoted.

Key words: Gastrointestinal neoplasms, Ginger and citri reticulatae stomach-warming ointment, Acupoint sticking therapy, Nausea, Vomiting, Treatment outcome, Quality of life

摘要： 背景　化疗所致恶心呕吐（CINV）是肿瘤治疗过程中常见的不良反应之一。中药穴位贴敷作为中医特色疗法，在防治CINV方面可发挥一定疗效，研究穴位贴敷预防CINV，对于提高肿瘤患者化疗期间的生活质量具有重要意义。目的　了解姜橘暖胃膏穴位贴敷联合托烷司琼和地塞米松预防CINV的疗效。方法　纳入2018年5—12月在广州中医药大学第一附属医院、原广州军区总医院肿瘤科住院的胃肠道肿瘤化疗患者共140例为研究对象，采用随机数字表法分为姜橘暖胃膏组75例，对照组65例（剔除首次化疗前确认不能继续参与研究者）。后续过程中姜橘暖胃膏组脱落10例，对照组脱落4例。对照组在化疗时接受常规预防CINV方案（托烷司琼和地塞米松静脉推注），姜橘暖胃膏组在常规预防方案的基础上加予姜橘暖胃膏穴位贴敷。化疗第1~5天每日记录患者恶心呕吐情况及相关不良反应，于化疗第5天采用生活质量核心量表（QLQ-C30）评价生活质量。结果　姜橘暖胃膏组急性期CINV的有效控制率（ORR）与对照组比较（98.5%比91.2%），差异无统计学意义（P=0.10）；姜橘暖胃膏组延迟期CINV的ORR高于对照组（100.0%比81.3%），差异有统计学意义（P=0.02）。姜橘暖胃膏组第2~4天的呕吐发生率低于对照组，差异有统计学意义（P<0.05）。姜橘暖胃膏组患者第1~5天恶心发生率低于对照组，差异有统计学意义（P<0.05）。姜橘暖胃膏组患者总体生活质量较对照组改善（P<0.05），主要体现在疲乏和恶心呕吐、食欲丧失、腹泻、便秘等胃肠道症状方面（P<0.05）。两组解救治疗使用率比较，差异无统计学意义（P>0.05）。结论　姜橘暖胃膏穴位贴敷联合托烷司琼和地塞米松对延迟性CINV有效，并能缓解疲乏及胃肠道症状，提高患者总体的生活质量，可进一步研究推广。

关键词: 胃肠肿瘤, 姜橘暖胃膏, 穴位贴敷法, 恶心, 呕吐, 治疗结果, 生活质量

JIANG Mei,ZHOU Daihan,GUO Ran, et al. Clinical Effect of Ginger and Citri Reticulatae Stomach-warming Ointment Combined with Tropisetron and Dexamethasone in Preventing Chemotherapy-induced Nausea and Vomiting　[J]. Chinese General Practice, 2020, 23(16): 2051-2056. DOI: 10.12114/j.issn.1007-9572.2020.00.177.
蒋梅,周岱翰,郭然等. 姜橘暖胃膏穴位贴敷联合托烷司琼和地塞米松预防化疗所致恶心呕吐的临床疗效研究[J]. 中国全科医学, 2020, 23(16): 2051-2056. DOI: 10.12114/j.issn.1007-9572.2020.00.177.

References

［1］ROILA F，MOLASSIOTIS A，HERRSTEDT J，et al．2016 MASCC and ESMO guideline update for the prevention of chemotherapy-and-radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients［J］．Ann Oncol，2016，27（suppl 5）：119-133．DOI：10.1093/annonc/mdw270.
［2］ROILA F，HERRSTEDT J，AAPRO M，et al．Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference［J］．Ann Oncol，2010，21（suppl 5）：232-243．DOI：10.1093/annonc/mdq194.
［3］李丽，宋燕青，张四喜．化疗相关性恶心呕吐治疗药物研究进展［J］．药学与临床研究，2017，25（5）：421-424.
［4］National Comprehensive Cancer Network．NCCN clinical practice guidelines in oncology：antiemesis （version 2.2018）［EB/OL］．（2018-04-30）［2019-09-20］．http://www.nccn.org.
［5］WARR D．Bringing it all together in the treatment of CINV：application of current knowledge into routine clinical practice［J］．Support Care Cancer，2018，26（suppl 1）：29-33．
［6］RAPOPORT B L．Delayed chemotherapy-induced nausea and vomiting：pathogenesis，incidence，and current management［J］．Front Pharmacol，2017，8：19．
［7］RASHAD N，ABDEL-RAHMAN O．Differential clinical pharmacology of rolapitant in delayed chemotherapy-induced nausea an vomiting（CINV）［J］．Drug Des Devel Ther，2017，11：947-954．
［8］TAMURA K，AIBA K，SAEKI T，et al．Testing the effectiveness of antiemetic guidelines：results of a prospective registry by the CINV Study Group of Japan［J］．Int J Clin Oncol，2015，20（5）：855-865．DOI：10.1007/s10147-015-0786-7.
［9］SCHWARTZBERG L．Getting it right the first time: recent progress in optimizing antiemetic usage［J］．Support Care Cancer，2018，26（suppl 1）：19-27．DOI：10.1007/s00520-018-4116-2.
［10］CLARK-SNOW R A，VIDALL C，B?RJESON S，et al．Fixed combination antiemetic：a literature review on prevention of chemotherapy-induced nausea and vomiting using Netupitant/Palonosetron［J］．Clin J Oncol Nurs，2018，22（2）：e52-63．
［11］吴继萍，张雅丽．敷脐疗法在腹部术后胃肠功能恢复中的应用进展［J］．护士进修杂志，2017，32（22）：2038-2040．
［12］朱玲，靳芳．脐疗新探［J］．中国民族民间医药，2016，25（14）：56-57.
［13］丘平，申翔．穴位贴敷疗法治疗乳腺癌化疗后恶心呕吐50例疗效观察［J］．云南中医中药杂志，2016，37（3）：92-93．
［14］周松晶，李玉玲，史佳．穴位贴敷治疗化疗后恶心呕吐的临床有效性和安全性研究［J］．世界中西医结合杂志，2015，10（9）：1259-1261．DOI：10.13935/j.cnki.sjzx.150924.
［15］National Cancer Institute．Common terminology criteria for adverse events（CTCAE）［EB/OL］．［2019-08-13］．http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
［16］MOLASSIOTIS A，COVENTRY P A，STRICKER C T，
et al．Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting：the MASCC antiemesis tool［J］．Journal of Pain and Symptom Management，2007，34（2）：148-159．
［17］EORTC Quality of Life Group．EORTC QLQ-C30 scoring manual［M］．3rd ed．Brussels：QL Coordinator，2001.
［18］王伟兰，朱曼，郭代红，等．伊立替康临床应用的安全性研究［J］．中国药业，2011，20（3）：41-42．
［19］KOTAKA M，YOSHINO T，OBA K，et al．Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients withcuratively resected stageⅡ orⅢcolon cancer（JFMC41-1001-C2：JOIN trial）［J］．Cancer Chemother Pharmacol，2015，76（1）：75-84．DOI：10.1007/s00280-015-2757-0.

[1]	HAN Xiao, LI Qiyu, GE Pu, FAN Siyuan, LIU Diyue, WU Yibo, ZHANG Qingshuang. The Impact of Behavioral Lifestyle on Quality of Life in Hypertensive Patients [J]. Chinese General Practice, 2025, 28(26): 3248-3258.
[2]	WU Yue, WANG Xuetong, KE Bilian. Evaluation of Vision-related Quality of Life in Myopic Macular Degeneration Patients with Low Vision and Associated Factors [J]. Chinese General Practice, 2025, 28(23): 2908-2914.
[3]	WEN Min, ZHOU Yongling, LIU Jingjing, JIANG Keqing, LIU Juan, ZHU Xiaodan. The Effect and Mechanism of Compensatory Cognitive Training Based on mHealth APP on Stable Schizophrenia Patients [J]. Chinese General Practice, 2025, 28(22): 2819-2825.
[4]	MA Panpan, WANG Sijing, YOU Na, DING Dafa, LU Yibing. Efficacy and Safety of Danuglipron and Orforglipron in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis [J]. Chinese General Practice, 2025, 28(21): 2679-2685.
[5]	ZHU Shengjie, DIAO Huaqiong, HANG Xiaoyi, SUN Wenjun. Network Meta-analysis of Different Traditional Chinese Medicine Injections for the Treatment of Posterior Circulatory Ischemic Vertigo [J]. Chinese General Practice, 2025, 28(14): 1795-1808.
[6]	LIU Caiping, ZHANG Yanhua, TANG Jianpin, WANG Chengpeng, XUE Fengfeng, WANG Huijuan, LI Chuanwei, ZHANG Guangya, LI Huafang. Efficacy and Safety of Long-acting Risperidone Microspheres in the Maintenance Treatment of Schizophrenia [J]. Chinese General Practice, 2025, 28(13): 1622-1627.
[7]	FAN Jianing, CHEN Jieting, WANG Ziqi, FAN Jinhe, JING Mingxia. Analysis of the Development Trajectory of Health-related Quality of Life in Middle-aged and Elderly Patients with Cardiometabolic Diseases and the Influencing Factors [J]. Chinese General Practice, 2025, 28(08): 923-932.
[8]	YAO Dingye, LUO Guiping, SUN Junsheng, REN Jingjing. Diagnosis and Treatment of Halitosis: a General Practice Perspective [J]. Chinese General Practice, 2025, 28(07): 900-904.
[9]	LI Hongmei, ZHANG Yimin, WANG Yong, ZHANG Yurong, JIA Xiao, YU Jingjing, SANG Die. Aerobic Exercise Improves Physique and Quality of Life in Breast Cancer Patients During Anthracycline-based Chemotherapy: a Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(03): 285-292.
[10]	QI Mingrui, WANG Wenjuan, TIAN Limin. Health-related Quality of Life of Elderly Hypertensive Population in Northwest China [J]. Chinese General Practice, 2025, 28(02): 199-207.
[11]	MA Huping, REN Rong, HOU Mei, YUAN Aiyun. Clinical Observation of the New Antiepileptic Drug Perampanel in the Treatment of Refractory Epilepsy in Children Aged 0-18 Years [J]. Chinese General Practice, 2025, 28(02): 250-256.
[12]	FENG Caixia, WANG Zengshuai, MU Hailin, YANG Hanxuan, TAMIR. Effect of Parkinson's Disease Management Model Dominated by Movement Disorder Specialists and Centered on Community Doctors [J]. Chinese General Practice, 2024, 27(34): 4280-4285.
[13]	YANG Can, LI Ning, LI Xuefei, ZHAO Li, XU Hao, SHI Qi, WANG Yongjun, LIANG Qianqian. Efficacy of Zang Bi Formula in Treating Arthritis and Its Pulmonary Complications in Rheumatoid Arthritis Interstitial Lung Disease Mice [J]. Chinese General Practice, 2024, 27(24): 3015-3022.
[14]	RAN Zhuorui, SUN Ruixin, JIA Jingyi, CHE Zhaoyu, LI Ruixi, HE Yaping, CHU Qiao. Advances in Life Goal Adjustment Ability of Cancer Patients and Its Effect on Physical and Mental Health [J]. Chinese General Practice, 2024, 27(23): 2822-2828.
[15]	YU Haiyan, WANG Haitang, DU Zhaohui. Effects of Intervention Based on Behavioral Change Wheel and Behavioral Change Technologys on the Behavior, Ambulatory Blood Pressure and Quality of Life in Patients with Hypertension [J]. Chinese General Practice, 2024, 27(22): 2714-2723.